

## IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

22 October 2021

### Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

MELBOURNE - Imagination Biosystems Limited (ASX: IBX) (the **Company**) gives notice that, between 15 October 2021 and 21 October 2021 the Company issued 3,904,910 fully paid ordinary shares (**Shares**) in the Company as the result of shareholders exercising their options in the Company.

The Company issued the above Shares without a disclosure document to investors under Part 6D.2 of the *Corporations Act 2001* (Cth) (**Act**).

### Notice under Section 708A(5)(e) of the Act

The Company hereby gives notice that:

1. the Company issued the shares without disclosure to investors under Part 6D.2 of the Act;
2. this notice is being given under section 708A(5)(e) of the Act;
3. as at the date of this notice the Company has complied with:
  - a. the provisions of Chapter 2M of the Act as they apply to the Company; and
  - b. section 674 of the Act; and
4. as at the date of this notice, there is no information that is “excluded information” within the meaning of Sections 708A(7) and 708A(8) of the Act.

**-ENDS**

### About Imagination Biosystems

Imagination Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagination Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

**This Announcement has been approved by the Disclosure Committee of Imagination Biosystems Limited**

For further information please visit [www.imaginationbiosystems.com](http://www.imaginationbiosystems.com)

#### U.S. Media Contact:

Matthew Wygant  
[matthew@biotechwriting.com](mailto:matthew@biotechwriting.com)  
+1-408-905-7630

#### Australian Media & Investor Relations:

Evonne Grosso, WE Communications  
[We-AUImaginationBiosystems@we-worldwide.com](mailto:We-AUImaginationBiosystems@we-worldwide.com)  
+61-3-9866-4722